Show simple item record

dc.contributor.authorDoebele, R
dc.contributor.authorPerez, L
dc.contributor.authorTrinh, H
dc.contributor.authorMartinec, M
dc.contributor.authorMartina, R
dc.contributor.authorRiehl, T
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorMeropol, N
dc.contributor.authorWong, W
dc.contributor.authorCrane, G
dc.date.accessioned2019-12-09T17:08:14Z
dc.date.available2019-12-09T17:08:14Z
dc.date.issued2019en
dc.identifier.citationDoebele R, Perez L, Trinh H, Martinec M, Martina R, Riehl T, et al. P1.01-83 Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients. Journal of Thoracic Oncology. 2019;14(10):S392.en
dc.identifier.doi10.1016/j.jtho.2019.08.798en
dc.identifier.urihttp://hdl.handle.net/10541/622529
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jtho.2019.08.798en
dc.titleComparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patientsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of Colorado, Aurora, CO/US,en
dc.identifier.journalJournal of Thoracic Oncologyen
dc.description.noteen


Files in this item

This item appears in the following Collection(s)

Show simple item record